Prognostic significance of cytoplasmic macrophage migration inhibitory factor expression in patients with squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy

Oncology Reports

Volumn 13, Issue 1, 2005, Pages 59-64

  Suzuki, Fumiyuki ^a   Nakamaru, Yuji ^a   Oridate, Nobuhiko ^a   Homma, Akihiro ^a   Nagahashi, Tatsumi ^a   Yamaguchi, Sanae ^a   Nishihira, Jun ^a   Furuta, Yasushi ^a   Fukuda, Satoshi ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemoradiotherapy; Head and neck squamous cell carcinoma

Indexed keywords

MACROPHAGE MIGRATION INHIBITION FACTOR;

ADULT; AGED; ARTICLE; CANCER STAGING; CHEMISTRY; CYTOPLASM; DOWN REGULATION; FEMALE; HEAD AND NECK TUMOR; HUMAN; MALE; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; CYTOPLASM; DOWN-REGULATION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; TREATMENT OUTCOME;

EID: 21644476542     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.13.1.59     Document Type: Article

References (30)

1. Pignon JP, Bourhis J, Domenge C and Designe L: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 355: 949-955, 2000. (Pubitemid 30148259)
2. Piccirillo JF and Feinstein AR: Clinical symptoms and comorbidity: significance for the prognostic classification of cancer. Cancer 77: 834-842, 1996. (Pubitemid 26061274)
3. Homma A, Furuta Y, Oridate N, et al: Prognostic significance of clinical parameters and biological markers in patients with squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy. Clin Cancer Res 5: 801-806, 1999. (Pubitemid 29180831)
4. Lee DJ, Koch WM, Yoo G, et al: Impact of chromosome 14q loss on survival in primary head and neck squamous cell carcinoma. Clin Cancer Res 3: 501-505, 1997. (Pubitemid 27211825)
5. Zeng Q, Smith DC, Suscovich TJ, et al: Determination of intermediate biomarker expression levels by quantitative reverse transcription-polymerase chain reaction in oral mucosa of cancer patients treated with liarozole. Clin Cancer Res 6: 2245-2251, 2000. (Pubitemid 30399190)
6. Bloom BR and Bennett B: Relation of the migration inhibitory factor (MIF) to delaved-type hypersensitivity reactions. Ann NY Acad Sci 169: 258-265, 1970.
7. Calandra T and Roger T: Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 3: 791-800, 2003. (Pubitemid 37328657)
8. Pozzi LA and Weiser WY: Human recombinant migration inhibitory factor activates human macrophages to kill tumor cells. Cell Immunol 145: 372-379, 1992.
9. Calandra T, Bernhagen J, Mitchell RA and Bucala R: The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 179: 1895-1902, 1994. (Pubitemid 24155670)
10. Shimizu T, Ohkawara A, Nishihira J and Sakamoto W: Identification of macrophage migration inhibitory factor (MIF) in human skin and its immmunohistochemical localization. FEBS Lett 381: 199-202, 1996. (Pubitemid 26080339)
11. Donnelly SC, Haslett C, Reid PT, el al: Regulatory role foimacrophage migration inhibitory factor in acute respiratory distress syndrome. Nat Med 3: 320-323, 1997. (Pubitemid 27112930)
12. Shimizu T, Abe R, Nakamura H, el al: High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis. Biochem Biophys Res Commun 264: 751-758, 1999.
13. Nakamaru Y, Oridate N, Nishihira J, et al: Macrophage migration inhibitory factor in allergic rhinitis: its identification in eosinophils at the site of inflammation. Ann Otol Rhinol Laryngol 113: 205-209, 2004. (Pubitemid 38337764)
14. Lan HY, Yang N, Nikolic-Paterson DJ, et al: Expression of macrophage migration inhibitory factor in human glomerulonephritis. Kidney Int 57: 499-509, 2000. (Pubitemid 30430641)
15. Meyer-Siegler K and Hudson PB: Enhanced expression of macrophage migration inhibitory factor in prostatic adenocarcinoma metastases. Urology 48: 448-452, 1996. (Pubitemid 26317487)
16. Nishihira J, Koyama Y and Mizue Y: Identification of macrophage migration inhibitory factor in human leukemia HL-60 cells and its induction by lipopolysaccharide. Biochem Mol Biol Int 40: 861-869, 1996. (Pubitemid 26419808)
17. Takahashi, N, Nishihira, J, Sato, Y, et al: Involvement of macrophage migration inhibitory factor (MIF) in the mechanism of tumor cell growth. Mol Med 4: 707-714, 1998. (Pubitemid 29051376)
18. Kamimura A, Kamachi M, Nishihira J, et al: Intracellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocarcinoma of the lung. Cancer 89: 334-341, 2000. (Pubitemid 30489881)
19. Bando H, Matsumoto G, Bando M, et al: Expression of macrophage migration inhibitory factor in human breast cancer: association with nodal spread. Jpn J Cancer Res 93: 389-396, 2002. (Pubitemid 34506248)
20. Dabbous MK, North SM, Haney L, Tipton DA and Nicolson GL: Effects of mast cell-macrophage interactions on the production of collagenolytic enzymes by metastatic tumor cells and tumor-derived and stromal fibroblasts. Clin Exp Metastasis 13: 33-41, 1995.
21. Hermanek P: Union Internationale Contre le Cancer. TNM Classification of Malignant Tumours. Springer-Verlag, Berlin, pp13-29, 1987.
22. Wright TC, Ferenczy A and Kurman RJ: Carcinoma and other tumors of the cervix. 4th edition. Springer-Verlag, Berlin, pp279-326, 1994.
23. Brown JM and Giaccia AJ: The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 58: 1408-1416, 1998. (Pubitemid 28193601)
24. Nordsmark M, Overgaard M and Overgaard J: Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 41: 31-39, 1996. (Pubitemid 26396294)
25. Brizel DM, Dodge RK, Clough RW and Dewhirst MW: Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 53: 113-117, 1999.
26. Koong AC, Denko NC, Hudson KM, et al: Candidate genes for the hypoxic tumor phenotype. Cancer Res 60: 883-887, 2000. (Pubitemid 30129520)
27. Bernhagen J, Mitchell RA, Calandra T, et al. Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry 33: 14144-14155, 1994. (Pubitemid 24382359)
28. Bacher M, Metz CN, Calandra T, et al: An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci USA 93: 7849-7854, 1996. (Pubitemid 26277127)
29. Chesney J, Metz C, Bacher M, et al. An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol Med 5: 181-191, 1999. (Pubitemid 29252666)
30. Ogawa H, Nishihira J, Sato Y, et al: An antibody for macrophage migration inhibitory factor suppresses tumour growth and inhibits tumour-associated angiogenesis. Cytokine 12: 309-314, 2000. (Pubitemid 30449820)